Diffuse large B-cell lymphoma trials in China
133 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 2Not yet recruitingTrial-stage medicine
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
- Where
- Shanghai
- Age
- 18 years and over
- People
- 50
- Run by
- Ruijin Hospital
See details and how to joinNCT06062641Registry updated 2023-11-07
Phase 2RecruitingTrial-stage medicine
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Where
- Beijing
- Age
- 14 years to 85 years
- People
- 100
- Run by
- Beijing Tongren Hospital
See details and how to joinNCT06081478Registry updated 2023-10-13
Phase 2RecruitingTrial-stage medicine
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
- Where
- Jinan, Nanchang
- Age
- 18 years to 70 years
- People
- 31
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT05933967Registry updated 2023-08-15
No phaseRecruitingResearch participation
Frontline of ASCT in High-risk DLBCL
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 175
- Run by
- Peking University People's Hospital
See details and how to joinNCT05831865Registry updated 2023-05-06
Phase 1RecruitingTrial-stage medicine
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
- Where
- Hangzhou, Ningbo
- Age
- 18 years to 75 years
- People
- 24
- Run by
- Ningbo No. 1 Hospital
See details and how to joinNCT05659628Registry updated 2022-12-21
Phase 2RecruitingTrial-stage medicine
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 50
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT05552937Registry updated 2022-09-23
No phaseRecruitingTrial-stage medicine
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
- Where
- Changchun
- Age
- 18 years to 75 years
- People
- 64
- Run by
- oubai, MD/PhD
See details and how to joinNCT05040555Registry updated 2021-09-16
No phaseEnrolling by invitationResearch participation
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 407
- Run by
- Chinese Academy of Medical Sciences
See details and how to joinNCT04491721Registry updated 2020-07-29
All Diffuse large B-cell lymphoma trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.